Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis

Technology appraisal guidance
Reference number: TA276
Published: 27 March 2013

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)

Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD)
25 January 2013
(558.35 Kb 42 sec)

Adobe Acrobat reader required.

Adobe Acrobat reader required.

This page was last updated: 23 January 2013